Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-06T07:52:14.075Z Has data issue: false hasContentIssue false
  • English
  • Français

Deterioro de síntomas parkinsonianos después del tratamiento de alucinosis dopaminérgica con olanzapina

Published online by Cambridge University Press:  12 May 2020

J. Rudolph ,
M. Ghaemi  and
S. Schmülling
J. Rudolph
Affiliation:
Clínica Neurológica. Universidad de Köln, Köln, Alemania
M. Ghaemi
Affiliation:
Clínica Neurológica. Universidad de Köln, Köln, Alemania
S. Schmülling
Affiliation:
Clínica Neurológica. Universidad de Köln, Köln, Alemania
Get access

Resumen

El fármaco antipsicótico atípico olanzapina se ha propuesto para el tratamiento de la psicosis dopaminérgica en la enfermedad de Parkinson (PD). Informamos sobre un paciente de 68 años de edad que desarrolló un síndrome extrapiramidal acinético-rígido grave, acompañado por síntomas paranoides adicionales, después de un tratamiento de alucinosis óptica en PD con olanzapina. La olanzapina puede también inducir efectos secundarios extrapiramidales clínicamente pertinentes en los pacientes con PD.

Keywords

psicosis dopaminérgicaenfermedad de Parkinson idiopáticaolanzapinatrastorno delirante orgánico
Type
Informe clínico
Information
European Psychiatry (Ed. Española) , Volume 7 , Issue 2 , March 2000 , pp. 122 - 124
Copyright
Copyright © European Psychiatric Association 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Rudolph J, Ghaemi M, Schmiilling S. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. Eur Psychiatry 1999; 14: 356-57.

References

Bibliografía

Beasley, C, Tollefson, G, Tran, P. Safety of olanzapine. J Clin Psychiatr 1997; 58 (Suppl 10): 13–17.Google ScholarPubMed
Bymaster, FP, Calligaro, DO, Falcone, JF, Marsh, RD, Moore, NA, Trye, NC, et al. Radioreceptor binding profile of the atypical antipsychotic agent olanzapine. Neuropsycho-pharmacology 1996; 14: 87–96.CrossRefGoogle Scholar
Chambers, RA, Caracansi, A, Weiss, G. Olanzapine ove-dose cause of acute extrapyramidal symptoms. Am J Psychiatry 1998; 15: 1630–1.Google Scholar
Friedman, J. Olanzapine in the treatment of dopaminomi-metic psychosis in patients with Parkinson’s disease. Neurology 1998; 50: 1195–6.CrossRefGoogle ScholarPubMed
Friedman, JH, Lannon, MC. Clozapine-responsive tremor in Parkinson’s disease. Mov Disord 1990; 5: 225–9.CrossRefGoogle ScholarPubMed
Graham, JM, Sussman, JD, Ford, KS, Sagar, HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson’s disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998; 65: 774–7.CrossRefGoogle ScholarPubMed
Moshkovitz, C, Moses, H, Klawans, HL. Levodopa-induced psychosis: A kindling phenomenon. Am J Psychiatry 1978; 13: 669–75.Google Scholar
Rich, S, Friedman, JH, Ott, BR. Risperidone versus clozapine for the treatment of drug-induced psychosis in Parkinson’s patients. J Clin Psychiatr 1995; 56: 556–9.Google Scholar
Wolters, EC, Jansen, ENH, Tuynman-Qua, HG, Bergmans, PLM.Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1996; 47: 1085–7.CrossRefGoogle ScholarPubMed
Tolosa, ESValldeoriola, F, Marti, MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994;44 (Supp 6): S35–S44.Google ScholarPubMed